If you've spent any time researching Contrave, you've almost certainly encountered it: a bold, capitalized warning at the top of the prescribing information about suicidal thoughts and behaviors. The black box on Contrave is a regulatory artifact inherited from one of its two active ingredients. Understanding where the warning came from, what the clinical evidence actually shows, and how to think about it in the context of your own health can turn that moment of alarm into an informed decision.
What Contrave Actually Is and Why It Contains an Antidepressant
Contrave is a prescription medication approved by the FDA in September 2014 for chronic weight management. It's designed for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It's meant to be used alongside a reduced-calorie diet and increased physical activity.
What makes Contrave distinct from other weight-loss medications is its combination of two drugs: naltrexone (8 mg per tablet) and bupropion (90 mg per tablet), both in extended-release form. Each targets a different part of the brain's appetite and reward circuitry.
Naltrexone is an opioid antagonist, originally approved for treating alcohol and opioid dependence. It blocks opioid receptors in the brain, which are involved in the rewarding aspects of eating. The role of bupropion in Contrave and its known effects on mood and mental health. Bupropion, a key component of Contrave, acts as a norepinephrine-dopamine reuptake inhibitor. Increasing these neurotransmitters in the brain helps regulate appetite and cravings. While primarily included for weight management, bupropion’s stimulant-like effects can influence mood, sometimes causing insomnia, anxiety, or mild mood changes in some individuals. There are potential mental health effects of Contrave, and the importance of monitoring patients for psychiatric symptoms.
The combination is thought to work synergistically. Bupropion activates hypothalamic neurons that suppress appetite, while naltrexone blocks an auto-inhibitory feedback loop that would normally dampen that signal. The result is a more sustained reduction in hunger and cravings than either drug achieves alone. The important thing to understand is that bupropion wasn't included in Contrave because patients need an antidepressant. It was included because its neurochemical effects on dopamine and norepinephrine are useful for appetite regulation. But because bupropion belongs to the antidepressant drug class, Contrave inherits the regulatory requirements that come with that classification.
Precautions and Contraindications
Before starting Contrave, both patients and healthcare providers must carefully weigh a range of precautions and contraindications to ensure safe and effective use. Contrave is not suitable for everyone, and understanding who should avoid the medication is essential to minimizing risks, especially those related to mental health. Contrave is contraindicated in several specific populations. Individuals with uncontrolled high blood pressure should not use Contrave, as the medication can increase blood pressure and heart rate, potentially worsening pre-existing cardiovascular conditions. Similarly, anyone with a history of seizures or conditions that increase seizure risk should avoid Contrave. This is because bupropion, one of Contrave’s active ingredients, is known to lower the seizure threshold. People with a current or past diagnosis of eating disorders like anorexia nervosa or bulimia are also advised against using Contrave, as these conditions further elevate seizure risk. Those who are dependent on opioids, currently using opioid medications, or undergoing treatment for opioid dependence should not take Contrave due to naltrexone’s opioid antagonist properties, which can precipitate sudden and severe withdrawal symptoms. Additionally, patients who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days, or who have a known allergy to naltrexone, bupropion, or any component of Contrave, should not use the medication. Women who are pregnant, planning to become pregnant, or breastfeeding should avoid Contrave, given the potential risks to the fetus or nursing infant.
The Black Box Warning: What It Says and Where It Came From
The FDA black box warning associated with Contrave focuses on the risk of suicidal thoughts and behaviors, particularly due to the bupropion component. In 2004, the FDA conducted a meta-analysis of short-term, placebo-controlled trials involving approximately 4,400 pediatric patients taking various antidepressants. The analysis found a roughly doubled risk of suicidal thinking or behavior, about 4% of patients on antidepressants versus about 2% on placebo, though no completed suicides occurred in any of the trials. Based on these findings, the FDA issued a black box warning for all antidepressants regarding pediatric use in 2005.
In 2007, the FDA extended the warning to include young adults aged 18 to 24, based on a broader meta-analysis of approximately 77,000 adult patients across 295 trials of eleven antidepressants. That same analysis found no increased risk among adults over 24 and a statistically significant reduction in suicidality among adults aged 65 and older.
This is a class-wide warning applied to every antidepressant on the market. It wasn't triggered by something specific about bupropion. Because Contrave contains bupropion, which is classified as an antidepressant, the warning automatically attaches to Contrave's label, even though it is not prescribed for depression and even though the patient population taking it for weight loss is fundamentally different from the population in the original antidepressant trials.
What Bupropion's Own Data Shows About Suicidality
A meta-analysis examined suicidality data from placebo-controlled clinical trials of bupropion in adults. The analysis looked at over 8,000 subjects across multiple studies and found no statistically significant difference in suicidal ideation or behavior between patients taking bupropion and those taking a placebo. The incidence of suicidal behavior or ideation was 0.53% in the bupropion group versus 0.48% in the placebo group.
This aligns with bupropion's unique pharmacological profile. Unlike SSRIs and SNRIs, the antidepressant classes that drove much of the original concern about suicidality, bupropion does not significantly affect serotonin. It acts primarily on dopamine and norepinephrine systems. Bupropion is devoid of clinically significant serotonergic effects, which sets it apart mechanistically from the drugs most scrutinized in the FDA's original meta-analyses.
It's also worth noting that a 2009 FDA warning about suicidal thoughts associated with bupropion, specifically when used for smoking cessation, was later removed in 2016 after a large, randomized follow-up trial failed to confirm the risk. This is one of the few instances where the FDA has walked back a safety warning on a drug, and it speaks to the evolving understanding of bupropion's neuropsychiatric profile.
What Contrave's Own Clinical Trials Revealed About Mental Health
Contrave was evaluated in a series of Phase 3 clinical trials known as the Contrave Obesity Research (COR) program, including COR-I, COR-II, and COR-BMOD.
Efficacy Context
It helps to understand what Contrave does. In the COR-II trial, patients on Contrave lost an average of 6.4% of their body weight over 56 weeks, compared with 1.2% in the placebo group. More than half (50.5%) of patients on Contrave achieved at least 5% weight loss, compared to 17.1% in the placebo group.
Psychiatric Safety Profile
When it comes to mental health outcomes specifically, the pooled trial data tells a nuanced story. Psychiatric adverse events were reported in 22.2% of patients taking Contrave versus 15.5% on placebo. That sounds like a significant gap, but the details matter. The most common psychiatric side effect was sleep disturbance, reported in 13.8% of Contrave patients versus 8.4% on placebo. This is consistent with bupropion's known stimulant-like properties as a dopamine and norepinephrine reuptake inhibitor. Insomnia is one of its most frequently reported side effects across all its FDA-approved uses. One must learn strategies for managing side effects, recognizing warning signs, and knowing when to consult a healthcare professional regarding mental health concerns while taking Contrave.
Depression was reported in 6.3% of the Contrave group versus 5.9% on placebo, a difference so small it doesn't reach statistical significance. Anxiety was reported in 6.1% of the Contrave group versus 4.4% on placebo—slightly elevated, but again, modest. The pooled analyses did not show an increased risk of suicidal ideation or behavior in patients taking Contrave compared to placebo.
Patients were excluded from the trials if they had a serious psychiatric illness, were currently using psychiatric medications, or had a history of substance abuse within the past year. This means the trial population was psychiatrically healthier than many real-world patients who might be prescribed Contrave. The data is reassuring for people without serious psychiatric conditions, but it can't fully speak to how the medication performs in patients who already live with depression, anxiety, or other mental health challenges.
The Obesity-Depression Connection: Why Mental Health Monitoring Matters Regardless
Any conversation about Contrave and mental health would be incomplete without acknowledging the complex, bidirectional relationship between obesity and mood disorders. 43% of U.S. adults aged 20 and over who live with depression also have obesity. Obesity can contribute to depression through biological mechanisms, social stigma, and reduced quality of life, while depression can contribute to weight gain through changes in appetite and the side effects of certain psychiatric medications.
This means that many people considering Contrave may already be navigating mental health challenges, whether diagnosed or not. Weight bias and discrimination compound the issue, contributing to poor mental health outcomes independent of a person's actual weight. Mental health monitoring is important because the population that benefits most from weight-management medication is also the population that carries a higher baseline risk for depression and anxiety. Any thoughtful treatment plan should account for this overlap.
This is also where having the right clinical support makes a meaningful difference. Programs like Harbor pair weight-loss medication with ongoing clinical guidance, recognizing that effective weight management involves monitoring the full picture of a patient's health, including mental and emotional well-being. That kind of integrated approach reflects what the evidence consistently shows: outcomes improve when pharmacotherapy is combined with behavioral support and attentive follow-up.
What to Watch For and How to Talk to Your Prescriber
Understanding the context behind the warning doesn't mean dismissing it. Anyone starting Contrave should have a clear plan for mental health monitoring, not because the drug is uniquely dangerous, but because good clinical practice demands it.
- Symptoms to Monitor: The FDA prescribing information for Contrave lists specific changes that patients and their families should watch for, particularly during the first few months of treatment or after a dose change. These include new or worsening depression, anxiety, or agitation, panic attacks, irritability, hostility or aggression, impulsive behavior, restlessness, and thoughts of suicide or self-harm. If any of these emerge, the guidance is unambiguous: stop taking Contrave and contact your healthcare provider immediately.
- Having the Conversation: Before starting Contrave, have an open conversation with your prescriber about your mental health history. It's a clinically important discussion. If you have a history of depression, bipolar disorder, anxiety, or suicidal thoughts, your provider needs to weigh that against the potential benefits of the medication. Contrave's prescribing information specifically notes that antidepressant treatment can precipitate manic or hypomanic episodes in patients with bipolar disorder or risk factors for it. Ask your prescriber how they plan to monitor you. Will you have check-in appointments during the first few weeks? Is there a number to call if you notice changes between visits? Are there family members or close friends who should know what to look for?
- Who Should Be Especially Cautious: Based on the available evidence, the groups that warrant the most careful monitoring include adults under 25, people with a current or past history of depression or suicidal thoughts, people with bipolar disorder or a family history of bipolar disorder, and anyone currently taking other medications that affect brain chemistry, particularly other antidepressants, which should generally not be combined with Contrave without careful medical supervision.
The black box warning on Contrave is real, it's required, and it shouldn't be ignored. But it also shouldn't be the end of the conversation. It's the beginning of one. The warning exists because bupropion is classified as an antidepressant, and all antidepressants carry this label as a result of FDA decisions made between 2004 and 2007. When you look at bupropion's own clinical data in isolation, there's no statistically significant increase in suicidal ideation or behavior compared to placebo in adults. When you look at Contrave's Phase 3 trials specifically, the pooled data similarly show no elevated risk of suicidality. The most common psychiatric side effect is insomnia, a known and manageable consequence of bupropion's stimulant-like activity.
Frequently Asked Questions
When considering Contrave for weight management, it’s crucial to understand the range of possible side effects. Below, we answer common questions about the range of side effects linked to Contrave, distinguishing between common, mild, and serious adverse effects, including those affecting mental health.
What are the most common side effects of Contrave?
The most common side effects include nausea, constipation, headache, dizziness, dry mouth, diarrhea, and trouble sleeping. These are usually mild and often improve as your body adjusts to the medication.
Which mild side effects might I experience with Contrave?
Mild side effects can include fatigue, hot flashes, taste changes, unusual dreams, anxiousness or irritability, and mild allergic reactions such as rash or itchiness. Most are temporary and manageable.
Are there any serious side effects associated with Contrave?
Yes, serious side effects, though rare, can include increased blood pressure, increased heart rate, seizures, liver problems, severe allergic reactions, and risk of suicidal thoughts or behaviors. Seek medical attention if these occur.
Can Contrave cause changes in my mental health?
Contrave may cause mood changes, anxiety, agitation, or insomnia. While the risk of serious psychiatric side effects is low for most adults, monitoring for new or worsening symptoms is important.
How soon do side effects appear, and do they go away?
Common side effects like nausea or headache often appear within the first weeks of treatment and usually decrease over time. If symptoms persist or worsen, consult your healthcare provider.
Are there side effects specific to the bupropion component?
Bupropion can contribute to stimulant-like effects such as insomnia and anxiety. It is also linked to a small risk of seizures, especially at higher doses or in those with certain risk factors.
Is hair loss a possible side effect of Contrave?
Hair loss has been reported, but it is rare and often mild. Nutritional changes during weight loss may also contribute. Discuss persistent hair loss with your doctor.
Does Contrave cause sexual side effects?
Sexual side effects such as erectile dysfunction or vaginal dryness have been reported but are uncommon. If these persist, consult your healthcare provider for management options.
What should I do if I experience a severe reaction?
If you experience symptoms like chest pain, severe allergic reaction, difficulty breathing, or thoughts of self-harm, stop taking Contrave and seek emergency medical care immediately.
Will I have withdrawal symptoms if I stop taking Contrave?
Contrave is not associated with withdrawal symptoms. However, always talk to your doctor before discontinuing the medication to ensure a safe transition.
How can I manage mild side effects like nausea, headache, or insomnia?
Take Contrave with food (but avoid high-fat meals), stay hydrated, and maintain a regular sleep schedule. Most mild side effects improve as your body adjusts, but discuss persistent symptoms with your doctor.
What should I do if I experience mood changes or anxiety?
Monitor your mood and share any new or worsening symptoms with your healthcare provider promptly. Open communication helps ensure timely adjustments to your treatment plan if needed.
Are there strategies for tracking side effects over time?
Keep a daily log of your symptoms, medication doses, and any changes in mood or behavior. This information can help your doctor tailor your care and catch issues early.
Which warning signs mean I should contact my doctor right away?
Contact your doctor immediately if you notice new or worsening depression, anxiety, agitation, impulsive behavior, or thoughts of self-harm. These may require urgent evaluation or stopping the medication.
When should I seek emergency medical attention?
Seek emergency help if you experience severe allergic reactions (swelling, difficulty breathing), chest pain, seizures, or suicidal thoughts. Do not wait for a scheduled appointment in these situations.
Can family or friends help monitor my mental health while on Contrave?
Yes. Inform trusted people about possible warning signs so they can help observe changes and encourage you to seek help if needed.
How often should I check in with my healthcare provider when starting Contrave?
Schedule regular follow-ups, especially during the first few months or after dose changes. Early check-ins help detect and manage side effects promptly.
What if I want to stop taking Contrave because of side effects?
Do not stop Contrave abruptly without consulting your doctor. They can guide you on safe discontinuation and discuss alternative options if necessary.
At the same time, the clinical trials excluded patients with serious psychiatric conditions, which means the evidence base has real limitations for people who carry a heavier mental health burden. And the bidirectional relationship between obesity and depression means that mental health monitoring deserves to be front and center in any weight-management treatment plan, regardless of which medication you take. The most productive thing you can do with the information in this post is to bring it up in a conversation with your healthcare provider. A black box warning is a tool for informed decision-making. Understanding the difference is what turns anxiety about a label into confidence in a treatment plan.
Sources:
- Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults — P&T Journal (PMC)
- FDA Contrave Prescribing Information (2025) — FDA
- Update on Drug Safety Evaluation of Naltrexone/Bupropion for the Treatment of Obesity — Expert Opinion on Drug Safety
- Meta-Analysis of Suicidality in Placebo-Controlled Clinical Trials of Adults Taking Bupropion — Primary Care Companion to the Journal of Clinical Psychiatry (PMC)
- The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? — Frontiers in Psychiatry (PMC)
- Antidepressants' Black-Box Warning — 10 Years Later — New England Journal of Medicine
- Intended and Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review — Health Affairs
- A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-Related Risk Factors (COR-II) — Obesity (PMC)
- A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor — Primary Care Companion to the Journal of Clinical Psychiatry (PMC)
- Antidepressants and the FDA's Black-Box Warning: Determining a Rational Public Policy in the Absence of Sufficient Evidence — AMA Journal of Ethics
- Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified — Frontiers in Psychiatry
- Fast Facts – Mental Health and Obesity — STOP Obesity Alliance, George Washington University
- Bupropion-Naltrexone (Contrave) for Weight Loss — Harbor